ストックスクリーナーアプリを入手
4.69
4.22%
0.19
アフターアワーズ：
4.40
-0.29
-6.18%
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech regains compliance with Nasdaq minimum bid price rule - Investing.com India
Moleculin Biotech Regains Nasdaq Compliance - TipRanks
Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A - GuruFocus
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
CapEx per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView — Track All Markets
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus
HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq
Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters Inducement Offer Agreements - TipRanks
Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com South Africa
Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India
Moleculin Biotech raises $6.5 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative
Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan
Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io
Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus
Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks
Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com Nigeria
Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView — Track All Markets
Moleculin stock rises as AML trial enrollment reaches 78% - Investing.com
Moleculin reports 78% enrollment in AML treatment trial - Investing.com
Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com South Africa
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal 'MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - The Manila Times
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Sahm
Moleculin (Nasdaq: MBRX) Tracks Toward 45-Patient MIRACLE AML Readout in Q1 2026 - Stock Titan
The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus - RTTNews
Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com Australia
After tax other income/expense of Moleculin Biotech, Inc. – BER:MOL0 - TradingView — Track All Markets
Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks
Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus
Moleculin enters research agreement for brain cancer treatment - Investing.com
Moleculin Announces New Annamycin Collaboration in Brain Tumors - The Manila Times
Moleculin Biotech, Inc. Partners with CIC biomaGUNE for Preclinical Research on Annamycin as a Treatment for Glioblastoma Multiforme - Quiver Quantitative
Moleculin announces new Annamycin collaboration in brain tumors - marketscreener.com
Moleculin (Nasdaq: MBRX) joins CIC biomaGUNE to study Annamycin in GBM models - Stock Titan
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (MBRX) Price Target Increased by 2,399.99% to 170.00 - Nasdaq
Net debt of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
After tax other income/expense of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Basic earnings per share (basic EPS) of Moleculin Biotech, Inc. – LS:A41SET - TradingView
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Geopolitics Watch: Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Reactions & Fast Momentum Entry Tips - BỘ NỘI VỤ
Moleculin Biotech, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Financial Data Forecasts Estimates and Expectations | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Dividend historical data and projections - marketscreener.com
Moleculin Biotech, Inc.: Target Price Consensus and Analysts Recommendations | MOL0 | US60855D4088 - marketscreener.com
How supply shortages influence Moleculin Biotech Inc. (MOL) stockPortfolio Profit Report & Precise Swing Trade Alerts - Newser
Moleculin Biotech Inc (FRA:MOL0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Moleculin Biotech Inc (FRA:MOL0) Stock Earnings Transcripts - GuruFocus
Why Moleculin Biotech Inc. stock attracts global investors2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Enterprise value to EBITDA ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
0.39%
1.90%
大文字化:
|
ボリューム (24 時間):